Physician profile
David K Dong
NPI 1336155258
$1,211.22
in general payments reported to CMS, 2019-2025
14 companies · $225 in 2025
The $225 reported for 2025 was more than what 77% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $262 · 2020: $120 · 2021: $30.22 · 2022: $216 · 2023: $224 · 2024: $135 · 2025: $225.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $583.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $583.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $227.99 | 2019-2025 | Vaxelis, Vaxneuvance, Gardasil 9 |
| Glaxosmithkline, LLC. | $200.33 | 2019-2025 | Bexsero, Shingrix |
| Novo Nordisk INC | $140.74 | 2019-2022 | |
| Sanofi Pasteur INC. | $118.42 | 2020-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $115.00 | 2019 | |
| Sobi, INC | $105.33 | 2019-2023 | |
| Hologic Sales and Service, LLC | $80.66 | 2024-2025 | Aptima |
| Cranial Technologies, INC | $67.02 | 2019-2025 | Doc Band |
| Phadia US INC. | $62.23 | 2019-2025 | Immunocap |
| Verrica Pharmaceuticals INC. | $25.45 | 2023 | Ycanth |
| Pfizer INC. | $19.39 | 2023 | |
| Corcept Therapeutics | $18.56 | 2025 | Korlym |
| Abbvie INC. | $15.96 | 2021 | |
| Sumitomo Pharma America, INC. | $14.14 | 2024 | Gemtesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Dong listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.